STOCK TITAN

Zentalis Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that its CEO, Anthony Sun, MD, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 1:30 p.m. ET. A live webcast will be available on the company’s website, with an archived version accessible afterwards.

Zentalis focuses on developing novel small molecule therapeutics targeting cancer pathways, including its lead program, ZN-c5, an oral selective estrogen receptor degrader for breast cancer. For more information, visit www.zentalis.com.

Positive
  • None.
Negative
  • None.

NEW YORK and SAN DIEGO, May 28, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 1:30 p.m. ET.

A live webcast of the fireside chat will be accessible through the Investors section of the Company’s website at www.zentalis.com. Following the event, an archived webcast will be available on the Zentalis website.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental biological pathways in cancer. In addition to its lead program, ZN-c5, an oral selective estrogen receptor degrader (SERD) for estrogen-receptor-positive, HER2-negative breast cancer, the Company is developing a broad pipeline of oncology candidates, targeting areas of major unmet medical need. The Company has offices in New York and San Diego. For more information, please visit www.zentalis.com.

Contacts

Investor Contact:

Thomas Hoffmann

Solebury Trout

1.646.378.2931

thoffmann@soleburytrout.com

Media Contact:

Julia Deutsch

Solebury Trout

1.646.378.2967

jdeutsch@soleburytrout.com


FAQ

When is the fireside chat featuring Zentalis Pharmaceuticals' CEO?

The fireside chat with Anthony Sun, CEO of Zentalis Pharmaceuticals, will take place on June 4, 2020, at 1:30 p.m. ET.

How can I access the Zentalis Pharmaceuticals fireside chat?

You can access the live webcast of the Zentalis Pharmaceuticals fireside chat through the Investors section of their website.

What is Zentalis Pharmaceuticals known for?

Zentalis Pharmaceuticals is known for developing novel small molecule therapeutics that target fundamental pathways in cancer, including the lead program ZN-c5 for breast cancer.

What is the stock symbol for Zentalis Pharmaceuticals?

The stock symbol for Zentalis Pharmaceuticals is ZNTL.

Zentalis Pharmaceuticals, Inc.

NASDAQ:ZNTL

ZNTL Rankings

ZNTL Latest News

ZNTL Stock Data

217.36M
64.53M
3.83%
98.06%
6.97%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO